PharmaShots Weekly Snapshots (November 08 – 12, 2021)

Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer’s Disease at CTAD 2021

Published: Nov 12, 2021 | Tags: Eisai, Lecanemab, P-IIb, Study 201 Study, Alzheimer’s Disease, CTAD 2021

Novo Nordisk’s Wegovy (semaglutide) Receives CHMP’s Recommendation for Approval to Treat Obesity

Published: Nov 12, 2021 | Tags: Novo Nordisk, Wegovy, semaglutide, CHMP, Approval, Obesity

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Published: Nov 12, 2021 | Tags: Oncorus, Gaeta, IL-12, Immune Checkpoint Inhibitors, Cancer

Boehringer Ingelheim and Eli Lilly Report the US FDA’s Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Published: Nov 12, 2021 | Tags: Boehringer Ingelheim, Eli Lilly, US, FDA, sNDA, Priority Review, Jardiance, empagliflozin, HFpEF

Celltrion’s CT-P59 (regdanvimab) Receives CHMP’s Positive Opinion for the Treatment of COVID-19

Published: Nov 12, 2021 | Tags: Celltrion, CT-P59, regdanvimab, CHMP, COVID-19

Organon to Acquire Forendo for ~$954M

Published: Nov 12, 2021 | Tags:  Organon, Acquire, Forendo, ~$954M

Secarna Signs Multiple Agreement with Achilles Therapeutics to Develop Optimized T cell Therapies

Published: Nov 11, 2021 | Tags: Secarna, Achilles Therapeutics, Optimized T cell Therapies

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Published: Nov 11, 2021 | Tags: Horizon, P-IIb, Trial, HZN-825, Diffuse Cutaneous Systemic Sclerosis

Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Published: Nov 11, 2021 | Tags: Mustang Bio, Leiden University Medical Centre, Lentiviral Gene Therapy, RAG1 Severe Combined Immunodeficiency

Finch Reports Results of CP101 in P-II PRISM-EXT Trial for the Prevention of Recurrent C. difficile Infection

Published: Nov 11, 2021 | Tags: Finch, CP101, P-II, PRISM-EXT Trial, Recurrent C. difficile Infection

I-Mab Entered into a Collaboration with Jumpcan to Develop and Commercialize Eftansomatropin Alfa (TJ101) in Mainland China

Published: Nov 11, 2021 | Tags: I-Mab, Jumpcan, Eftansomatropin Alfa, TJ101, China

Genentech Enters into a Multi-Year Research Collaboration with Novome Biotechnologies to Develop Targets Against Inflammatory Bowel Disease

Published: Nov 11, 2021 | Tags: Genentech, Novome Biotechnologies, Targets, Inflammatory Bowel Disease

Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC

Published: Nov 10, 2021 | Tags: Exelixis, P-III, CONTACT-01 Trial, Cabometyx, cabozantinib, Tecentriq, atezolizumab, Metastatic Non-Small Cell Lung Cancer

Zai Lab Entered into an Exclusive License Agreement with Karuna Therapeutics to Develop and Commercialize KarXT (xanomeline-trospium) in Greater China

Published: Nov 10, 2021 | Tags: Zai Lab, Karuna Therapeutics, KarXT, xanomeline-trospium, Greater China

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021

Published: Nov 10, 2021 | Tags: AbbVie, Rinvoq, upadacitinib) P-III, SELECT-PsA 1, 2, Trials, Active Psoriatic Arthritis, ACR 2021

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China

Published: Nov 10, 2021 | Tags: Blueprint Medicines, Zai Lab, BLU-945, BLU-701, Greater China

Pfizer Signs a Commercialization Arrangement with Biohaven for Rimegepant to Treat Migraine

Published: Nov 10, 2021 | Tags: Pfizer, Biohaven, Rimegepant, Migraine

Coloplast to Acquire Atos Medical for ~$2.49B

Published: Nov 10, 2021 | Tags: Coloplast, Acquire, Atos Medical, ~$2.49B

Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine

Published: Nov 9, 2021 | Tags: Amgen, Aimovig, erenumab-aooe, P-lV, Study, Episodic, Chronic Migraine

Novartis Presents Two-Year Data of Cosentyx (secukinumab) in P-III JUNIPERA Study for JPsA and ERA at ACR 2021

Published: Nov 9, 2021 | Tags: Novartis, Cosentyx, secukinumab, P-III, JUNIPERA Study, JPsA, ERA, ACR 2021

Kronos Bio Signs a Multi-Year Collaboration with Tempus for Access to its Platform

Published: Nov 9, 2021 | Tags: Kronos Bio, Tempus, Platform, lanraplenib, KB-0742, Cancer Therapeutics

Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III Study Against COVID-19

Published: Nov 9, 2021 | Tags: Regeneron, REGEN-COV, casirivimab, imdevimab, P-III, Study, COVID-19

I-Mab Collaborates with Roche Diagnostics to Co-Develop CDx Solutions at the 4th CIIE (Shanghai)

Published: Nov 9, 2021 | Tags: I-Mab, Roche Diagnostics, CDx Solutions, 4th CIIE

Biotech Acquisition Company Entered into a Merger Agreement with Blade Therapeutics

Published: Nov 9, 2021 | Tags: Biotech Acquisition Company, Merger Agreement, Blade Therapeutics

Alcon to Acquire Ivantis for ~$475M

Published: Nov 8, 2021 | Tags: Alcon, Acquire, Ivantis, ~$475M

Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for HFpEF at ASN Kidney Week 2021

Published: Nov 8, 2021 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, P-III, EMPEROR-Preserved Trial, HFpEF, ASN Kidney Week 2021

Pfizer Reports Interim Results of Paxlovid (COVID-19 Oral Antiviral Therapy) in P-II/III EPIC-HR Study for the Treatment of COVID-19

Published: Nov 8, 2021 | Tags: Pfizer, Paxlovid, COVID-19, Antiviral Therapy, P-II/III, EPIC-HR Study, COVID-19

GSK Presents Results of Daprodustat in P-III ASCEND Program for the Treatment of Anemia due to Chronic Kidney Disease at ASN Kidney Week 2021

Published: Nov 8, 2021 | Tags: GSK, Daprodustat, P-III, ASCEND Program, Anemia, Chronic Kidney Disease, ASN 2021

Ascletis Entered into an Exclusive WW License Agreement with Suzhou Alphamab for ASC22 (envafolimab) to Treat Hepatitis B and Other Viral Diseases

Published: Nov 8, 2021 | Tags: Ascletis, Suzhou Alphamab, ASC22, envafolimab, Hepatitis B, Viral Diseases

BMS Collaborates with Inspirna to Evaluate Yervoy (ipilimumab) + RGX-104 (abequolixron) for the Treatment of Metastatic Endometrial Cancer

Published: Nov 8, 2021 | Tags: BMS, Inspirna, Yervoy, ipilimumab, RGX-104, abequolixron, Metastatic Endometrial Cancer

Related post: PharmaShots Weekly Snapshots (November 01 – 03, 2021)